glp 1 dpp 4 Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Dipeptidyl Peptidase 4: DPP4 -

The drug, developed in partnership with Massachusetts-based Kailera Therapeutics, achieved at least 5% weight loss in 88% of patients who received it, and 20% weight loss in 44.4% of participants

With the phenomenon of direct-to-patient DTP and programs like Lilly Direct, Hims and Hers (and other disrupters) compounding, and a growing roster of telehealth-style channels expanding the retail health ecosystem, the GLP-1 phenomenon has led to a broader mainstream passion for empowerment and self-care with more people aware of the opportunity of taking responsibility and action for themselves

Weight loss outcomes were comparable to those observed in RCTs such as the STEP trials 1-2

Previous studies of 2.4mg of semaglutide and low-dose tirzepatide at 5 mg have shown around 15 percent weight loss at a similar time frame